{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:03:37Z","timestamp":1777626217126,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/s10156-010-0102-4","type":"journal-article","created":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T04:32:44Z","timestamp":1282797164000},"page":"224-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetic\u2013pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units"],"prefix":"10.1016","volume":"17","author":[{"given":"Mao","family":"Hagihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1007\/s10156-010-0102-4_bib0005","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1007\/s00277-003-0764-4","volume":"82","author":"Link","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1007\/s10156-010-0102-4_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijantimicag.2003.11.002","article-title":"Empirical antifungal therapy","volume":"23","author":"Klastersky","year":"2004","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"10.1007\/s10156-010-0102-4_bib0015","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.ijantimicag.2005.08.007","article-title":"Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever","volume":"26","author":"Jun","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1007\/s10156-010-0102-4_bib0020","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/jac\/dki222","article-title":"The place for itraconazole in treatment","volume":"56","author":"Maertens","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s10156-010-0102-4_bib0030","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1473-3099(03)00831-4","article-title":"Management of Candida sepsis infections in critically ill patients","volume":"3","author":"Eggimann","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1007\/s10156-010-0102-4_bib0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s001340050552","article-title":"Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care","volume":"24","author":"Vincent","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1007\/s10156-010-0102-4_bib0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10096-002-0730-4","article-title":"Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators","volume":"21","author":"Buchner","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1007\/s10156-010-0102-4_bib0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10096-007-0316-2","article-title":"Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study","volume":"26","author":"Dimopoulos","year":"2007","journal-title":"Eur J Clin Microb Infect Dis"},{"key":"10.1007\/s10156-010-0102-4_bib0050","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/archinte.1989.00390100145030","article-title":"Risk factors for hospital-acquired candidemia. A matched case-control study","volume":"149","author":"Wey","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1007\/s10156-010-0102-4_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/321811","article-title":"Risk factors for Candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey","volume":"33","author":"Blumberg","year":"2001","journal-title":"Clin Infect Dis."},{"key":"10.1007\/s10156-010-0102-4_bib0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microb Rev"},{"key":"10.1007\/s10156-010-0102-4_bib0065","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes.","volume":"79","author":"Patterson","year":"2000","journal-title":"I3 Aspergillus Study Group. Medicine (Baltimore)"},{"key":"10.1007\/s10156-010-0102-4_bib0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1007\/s10156-010-0102-4_bib0075","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1086\/383052","article-title":"Empirical antifungal therapy in treating febrile neutropenic patients","volume":"39","author":"Wingard","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s10156-010-0102-4_bib0080","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/AAC.37.10.2224","article-title":"Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations","volume":"37","author":"Hostetler","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0085","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/45.3.371","article-title":"Antifungal activity of itraconazole compared with hydroxyl-itraconazole in vitro","volume":"45","author":"Odds","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1439-0507.1999.00505.x","article-title":"Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"10.1007\/s10156-010-0102-4_bib0095","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1439-0507.1999.00518.x","article-title":"Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"10.1007\/s10156-010-0102-4_bib0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1128\/AAC.47.4.1179-1186.2003","article-title":"In vivo pharmacodynamics of antifungal drugs in treatment of Candidiasis","volume":"47","author":"David","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0732-8893(00)00173-5","article-title":"A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time\u2013kill methodology.","volume":"38","author":"Burggess","year":"2000","journal-title":"Diagn Microbil Infect Dis"},{"key":"10.1007\/s10156-010-0102-4_bib0110","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.42.11.3018","article-title":"Organism-dependent fungicidal activities of azoles","volume":"42","author":"Manavathu","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0115","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1128\/AAC.35.10.2053","article-title":"Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study","volume":"35","author":"Schafer-Korting","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/BF01716289","article-title":"Influence of serum protein binding on the in vitro activity of antifungal agents","volume":"23","author":"Schafer-Korting","year":"1995","journal-title":"Infection"},{"key":"10.1007\/s10156-010-0102-4_bib0125","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1128\/AAC.45.7.2018-2022.2001","article-title":"Influence of human serum on antifungal pharmacodynamics with Candida albicans","volume":"45","author":"Zhanel","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0130","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0135","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"43","author":"Andes","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-010-0102-4_bib0140","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7326\/0003-4819-135-6-200109180-00010","article-title":"Intravenous and oral itraconazole versus intravenous amphotericin B dexycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial","volume":"135","author":"Boogaerts","year":"2001","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1007\/s10156-010-0102-4_bib0145","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dki220","article-title":"Making sense of itraconazole pharmacokinetics","volume":"56","author":"Prentice","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1007\/s10156-010-0102-4_bib0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole: an overview","volume":"32","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"10.1007\/s10156-010-0102-4_bib0155","first-page":"8","article-title":"Monitoring the plasma level of itraconazole administration for prevention of fungal infection: the relationship between the plasma itraconazole level and several clinical parameters","volume":"25","author":"Okuda","year":"2008","journal-title":"Jpn J TDM"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X11705219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X11705219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10156-010-0102-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:47:52Z","timestamp":1761158872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X11705219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"alternative-id":["S1341321X11705219"],"URL":"https:\/\/doi.org\/10.1007\/s10156-010-0102-4","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic\u2013pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-010-0102-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}